Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 127 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Hoosier Cancer Research Network Clear all

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab; Drug
Lead sponsor: Nasser Hanna, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 15
States / cities: Duarte, California • Fort Wayne, Indiana • Goshen, Indiana + 9 more

Conditions: Breast Cancer
Interventions: Cisplatin, Rucaparib; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 27
States / cities: Fullerton, California • Los Angeles, California • Santa Maria, California + 22 more

Conditions: Breast Cancer, Brain Metastases, Adult
Interventions: Olaparib, Stereotactic Radiosurgery, Durvalumab, Physicians Choice systemic chemotherapy; Drug · Radiation
Lead sponsor: Colette Shen; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more

Conditions: Germ Cell Neoplasms, Testicular Neoplasms, Non Seminomatous Germ Cell Tumors, Mediastinal Neoplasms, Genital Neoplasms, Male, Genital Neoplasms, Female, Ovarian Neoplasms
Interventions: Pembrolizumab; Drug
Lead sponsor: Nasser Hanna, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Indianapolis, Indiana • Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: PTK787, Trastuzumab; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 8
States / cities: Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more

Conditions: Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer, Limited Stage Small-Cell Lung Cancer
Interventions: Durvalumab, Monalizumab, Carboplatin or Cisplatin, Etoposide; Drug
Lead sponsor: Khalil Choucair; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 4
States / cities: Indianapolis, Indiana • Iowa City, Iowa • Detroit, Michigan + 1 more

Conditions: Ovarian Cancer
Interventions: Sorafenib, Topotecan; Drug
Lead sponsor: Daniela Matei, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Galesburg, Illinois • Evansville, Indiana • Fort Wayne, Indiana + 4 more

Conditions: Melanoma, Ocular Melanoma
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Suthee Rapisuwon; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 6
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more

Conditions: Transitional Cell Carcinoma of the Bladder
Interventions: Gemcitabine, Cisplatin, Sunitinib Malate, Radical Cystectomy; Drug · Procedure
Lead sponsor: Noah Hahn, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Gainesville, Florida • Indianapolis, Indiana • South Bend, Indiana + 1 more

Conditions: Breast Cancer
Interventions: Hydroxychloroquine (HCQ), Gedatolisib; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lung Cancer
Interventions: Amrubicin, Cyclophosphamide; Drug
Lead sponsor: Lawrence Einhorn; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Springdale, Arkansas • Newark, Delaware • Galesburg, Illinois + 7 more

Conditions: Lung Cancer, NSCLC, Brain Metastases
Interventions: Alectinib, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: Joshua Palmer; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Columbus, Ohio

Conditions: Pancreatic Cancer
Interventions: mFOLFIRINOX, Ramucirumab, Placebo; Drug · Other
Lead sponsor: Walid Shaib, MD; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 8
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 5 more

Conditions: Urothelial Carcinoma
Interventions: Tremelimumab; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Westwood, Kansas + 4 more

Conditions: Locally Advanced Renal Cell Carcinoma
Interventions: Zanzalintinib, Nivolumab; Drug
Lead sponsor: Qian Qin; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania • Dallas, Texas + 1 more

Conditions: Breast Cancer
Interventions: Tumor Sample, Serum Sample; Procedure
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
Interventions: Pembrolizumab Monotherapy, Ramucirumab, Paclitaxel; Drug
Lead sponsor: Harry H Yoon; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota • Milwaukee, Wisconsin

Conditions: Uveal Melanoma
Interventions: PAC-1, Entrectinib; Drug
Lead sponsor: Arkadiusz Z. Dudek, MD; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bladder Cancer
Interventions: Cisplatin, Gemcitabine, Bevacizumab; Drug
Lead sponsor: Christopher Sweeney, MBBS; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 11
States / cities: Chicago, Illinois • Galesburg, Illinois • Evansville, Indiana + 7 more

Conditions: Rectal Cancer
Interventions: Capecitabine, Irinotecan, EUS, Neoadjuvant Chemotherapy, Preoperative Radiation, Surgery, Adjuvant Chemotherapy; Drug · Procedure
Lead sponsor: Gabi Chiorean, MD; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 9
States / cities: Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more

Conditions: Aggressive Variant Prostate Carcinoma
Interventions: Zanzalintinib; Drug
Lead sponsor: Deepak Kilari; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
Interventions: Everolimus, Paclitaxel; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • Chicago, Illinois • Bloomington, Indiana + 7 more

Conditions: Bladder Cancer
Interventions: Nivolumab, Gemcitabine, Cisplatin; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • New York, New York + 4 more

Conditions: Combined Hepatocellular and Cholangiocarcinoma
Interventions: Tremelimumab, Durvalumab, Gemcitabine, Cisplatin; Drug
Lead sponsor: Mehmet Akce; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")

Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

Zanzalintinib in Men With Aggressive Variant Prostate Cancer

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma